Skip to main content

Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?

Archives of Gynecology and Obstetrics volume 288, pages 167–172 (2013)Cite this article

Abstract

Purpose

To evaluate human epididymis protein 4 (HE4) as an extrabiomarker to cancer antigen 125 (CA125) to improve the detection of ovarian carcinoma.

Methods

Sixty patients with ovarian carcinoma, 50 patients with benign ovarian tumors and 30 healthy women were included in the present study. Serum concentration of HE4 was assayed using ELISA technique, while CA125 was assayed using chemiluminescent enzyme immunoassay.

Results

The median CA125 and HE4 serum values were significantly higher among ovarian cancer patients when compared with healthy control However, the median serum levels of CA125 but not HE4 were significantly higher among patients with benign ovarian tumors as compared to healthy women. Based on the receiver operator characteristics curve analysis, HE4 had higher sensitivities than CA125 for the detection of ovarian cancer at 90, 95 and 98 % specificities and the combination of both markers yielded a higher sensitivity than either alone. However, CA125 but not HE4 had higher sensitivities for the detection of benign ovarian tumors at the same specificities. In addition, a positive correlation was observed between HE4 and CA125 among patients with ovarian carcinoma.

Conclusion

HE4 is a valuable marker for ovarian cancer diagnosis and when combined with CA125, they had a higher sensitivity at a set specificity, thus providing a more accurate predictor of ovarian cancer than either alone.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Moore R, Brown A, Miller M et al (2008) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108:402–408

    PubMed  Article  CAS  Google Scholar 

  2. Escudero J, Auge J, Filella X et al (2011) Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and non malignant diseases. Clin Chem 57:1534–1544

    PubMed  Article  CAS  Google Scholar 

  3. Suh K, Park S, Castro A et al (2010) Ovarian cancer biomarkers for molecular biosensors and translation medicine. Expert Rev Mol Diag 10:1069–1083

    Article  CAS  Google Scholar 

  4. Hartge P, Whittemore S, Itnyre J et al (1994) Rates and risks of ovarian cancer in subgroups of white women in the United States. Obstet Gynecol 84(5):760–764

    PubMed  CAS  Google Scholar 

  5. Kumar V, Fausto N, Abbas A (2005) Robbins & Cotran Pathologic basis of diseases, 7th edn. Saunders, Philadelphia

    Google Scholar 

  6. Banks E (2000) The epidemiology of ovarian cancer. In: Bartlett JMS (ed) Ovarian cancer: methods and protocols. Humana Press, Totowa

    Google Scholar 

  7. Bast RC (2003) Status of tumor markers in ovarian cancer screening. J Clin Oncol 21(10):200S–205S

    PubMed  Article  Google Scholar 

  8. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics 2009. CA Cancer J Clin 59:225–249

    PubMed  Article  Google Scholar 

  9. Heitz A, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. Int J Gynecol Obstet 95:S161–S192

    Article  Google Scholar 

  10. Huhtinen K, Suvitie P, Hissa J et al (2009) Serum HE4 concentration differentiates malignant ovarian tumors from ovarian endometriotic cysts. Br J Cancer 100:1315–1319

    PubMed  Article  CAS  Google Scholar 

  11. Rosen D, Atkinson J, Yu Y et al (2005) Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99:267–277

    PubMed  Article  CAS  Google Scholar 

  12. Sturgeon C, Duffy M, Stenman U et al (2008) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancer. Clin Chem 54:e11–e79

    PubMed  Article  CAS  Google Scholar 

  13. How S, Liam C, Jamalludin A (2006) Serum cancer antigen 125 in patients with pleural effusions. Med J Malaysia 61:558–563

    PubMed  CAS  Google Scholar 

  14. Havrilesky L, Whitehead C, Rubatt J et al (2008) Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrences. Gynecol Oncol 110:374–382

    PubMed  Article  CAS  Google Scholar 

  15. Gao L, Cheng GHY, Dong L et al (2011) The role of HE4 in ovarian cancer: inhibiting tumor cell proliferation and metastasis. J Int Med Res 39:1645–1660

    PubMed  Article  CAS  Google Scholar 

  16. Drapkin R, Von-Horsten HH, Lin Y et al (2005) Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometroid ovarian carcinomas. Cancer Res 65:2162–2169

    PubMed  Article  CAS  Google Scholar 

  17. Chen L (ed) (2010) Diagnostic Gynecologic and Obstetric Pathology, 2nd edn. : People’s Military Medical Press, Beijing, pp 268-394

  18. Kaku T, Ogawa S, Kawano Y et al (2003) Histological classification of ovarian cancer. Med Electron Microsc 36:9–17

    PubMed  Article  Google Scholar 

  19. Benedet JL, Bender H, Jones H et al (2000) FIGO staging classification and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on Gynecologic Oncology. Int J Gynecol Obstet 70:209–262

    Article  CAS  Google Scholar 

  20. Terry K, Skates S, Mok S et al (2004) Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 20:53–70

    PubMed  CAS  Google Scholar 

  21. Dutta S, Wang F, Fishman D (2010) The dire need to develop a clinically validated screening method for the detection of early stage ovarian cancer. Biomark Med 4:437–439

    PubMed  Article  Google Scholar 

  22. Badgwell D, Bast R (2007) Early detection of ovarian cancer. Dis Markers 23(5–6):397–410

    PubMed  CAS  Google Scholar 

  23. Moore R, Mc-Meekin D, Brown A et al (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40–46

    PubMed  Article  CAS  Google Scholar 

  24. Molina R, Filella X, Bruix J et al (1991) Cancer antigen 125 in serum and ascitic fluid for patients with liver disease. Clin Chem 37:1379–1383

    PubMed  CAS  Google Scholar 

  25. Nolen B, Velikokhatnaya L, Marrangoni A et al (2010) Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 117:440–445

    PubMed  Article  CAS  Google Scholar 

  26. Moore R, Brown A, Miller M et al (2008) Utility of a novel serum tumor biomarker HE4 in patients with endometroid adenocarcinoma of the uterus. Gynecol Oncol 110:196–201

    PubMed  Article  CAS  Google Scholar 

  27. Yamashita S, Heagerty K, Hashimoto T et al (2011) Prognostic significance of HE4 in pulmonary adenocarcinoma. Tumor boil 32:265–271

    Article  CAS  Google Scholar 

  28. Montagnana M, Lippi G, Ruzzenete O et al (2009) The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 23:331–335

    PubMed  Article  Google Scholar 

  29. Hellstrom I, Raycraft J, Hayden-ledbetter M et al (2003) The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63:3695–3760

    PubMed  Google Scholar 

  30. Hellstrom I, Hellstrom K (2008) SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol 622:15–21

    PubMed  Article  CAS  Google Scholar 

  31. Ayhan A, Guven S, Guven E et al (2007) Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand 86:484–490

    PubMed  Article  CAS  Google Scholar 

  32. Yin B, Lloyd K (2001) Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 276:27371–27375

    PubMed  Article  CAS  Google Scholar 

  33. Abdel-Azeez H, Labib H, Sharaf S et al (2010) HE4 and mesothelin: novel biomarker of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev 11(1):111–116

    PubMed  Google Scholar 

Download references

Conflict of interest

No conflict of interest to be reported.

Author information

Affiliations

  1. Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria University, Azarita, Alexandria, Egypt

    Amal Z. Azzam

  2. Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Azarita, Alexandria, Egypt

    Doaa I. Hashad

  3. Department of Pathology, Faculty of Medicine, Alexandria University, Azarita, Alexandria, Egypt

    Nahla A. F. Kamel

Authors
  1. Amal Z. Azzam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Doaa I. Hashad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nahla A. F. Kamel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Doaa I. Hashad.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Azzam, A.Z., Hashad, D.I. & Kamel, N.A.F. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?. Arch Gynecol Obstet 288, 167–172 (2013). https://doi.org/10.1007/s00404-013-2722-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-013-2722-2

Keywords

  • HE4
  • CA125
  • Ovarian cancer
  • Benign ovarian tumors
  • ROC curve